Cargando…

Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Wilkie, S, Picco, G, Foster, J, Davies, D, Julien, S, Cooper, L, Arif, S, Mather, S, Taylor-Papadimitriou, J, Burchell, J, Maher, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3300700/ http://dx.doi.org/10.1186/bcr1881

Ejemplares similares

Development of breast cancer immunotherapy using MUC1 retargeted T lymphocytes
por: Wilkie, S, et al.
Publicado: (2006)

Mouse models for pretesting of immunotherapeutic strategies for cancer patients
por: Burchell, JM, et al.
Publicado: (2003)

Latest developments in MUC1 immunotherapy
por: Taylor-Papadimitriou, Joyce, et al.
Publicado: (2018)

Understanding and exploiting changes in O-linked glycosylation in breast cancer
por: Julien, S, et al.
Publicado: (2008)

Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas
por: Picco, Gianfranco, et al.
Publicado: (2014)

Genetic engineering of pharmacologically regulated T cells, specific for breast cancer target antigens
por: Wilkie, S, et al.
Publicado: (2010)

A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1
por: Wilkinson, R W, et al.
Publicado: (2000)

The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL
por: Beatson, Richard, et al.
Publicado: (2015)

MUC1 modulates the tumor immune microenvironment through the engagement of Siglec-9
por: Beatson, Richard, et al.
Publicado: (2016)

A VHH-Based Anti-MUC1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to MUC1-Positive Cancer Cells
por: Rajabzadeh, Alireza, et al.
Publicado: (2021)

Immunotherapy of cancer
por: McKenzie, I
Publicado: (2003)

Targeting cytotoxic T lymphocytes for cancer immunotherapy
por: Maher, J, et al.
Publicado: (2004)

Cardiovascular changes in patients with acromegaly assessed by CMR
por: Zemrak, Filip, et al.
Publicado: (2012)

Chimeric maternal cells as T lymphocyte targets in pediatric SLE
por: Stevens, Anne M, et al.
Publicado: (2012)

Selection of circulating PD-1+ lymphocytes from cancer patients enriches for tumor-reactive and mutation-specific lymphocytes
por: Gros, Alena, et al.
Publicado: (2015)

Focused ultrasound and immunotherapy
por: Hurwitz, Mark
Publicado: (2015)

Towards an immunoscore for triple negative breast cancer (TNBC): lymphocytic infiltrate predicts outcome
por: Adams, Sylvia, et al.
Publicado: (2013)

Interactions between the breast cancer-associated MUC1 mucins and C-type lectin characterized by optical tweezers
por: Hadjialirezaei, Soosan, et al.
Publicado: (2017)

Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis
por: Blixt, Ola, et al.
Publicado: (2011)

Signal transduction in T lymphocytes
por: Cantrell, D
Publicado: (2005)

The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance
por: David, Justin, et al.
Publicado: (2014)

Retargeting of Viruses to Generate Oncolytic Agents
por: Verheije, M. H., et al.
Publicado: (2012)

Correction: Interactions between the breast cancer-associated MUC1 mucins and C-type lectin characterized by optical tweezers
por: Hadjialirezaei, Soosan, et al.
Publicado: (2018)

Rab23 is required for cardiac progenitor cell differentiation and positively-regulates Wnt11/AP-1 signalling in zebrafish
por: Jenkins, D, et al.
Publicado: (2012)

Prevalence of low back pain among elite Australian senior rowers
por: Wilkie, Kellie, et al.
Publicado: (2015)

PLU-1/Jarid1B contributes to estrogen-induced cell proliferation in the normal mammary gland and in breast cancer, and is required for embryonic survival
por: Catchpole, S, et al.
Publicado: (2010)

Functional analysis of the breast cancer associated transcriptional repressor PLU-1/JARID1B
por: Taylor-Papadimitriou, J, et al.
Publicado: (2006)

A11 ISOLATION OF NON-POLAR METABOLITES IN EXCRETORY/SECRETORY PRODUCTS FROM PARASITIC HELMINTHS AND THEIR POTENTIAL AS IMMUNOTHERAPY IN INFLAMMATORY BOWEL DISEASE
por: Siciliani, E A, et al.
Publicado: (2022)

In vitro immunomonitoring of insect venom-allergic patients on immunotherapy
por: Cifuentes, Liliana, et al.
Publicado: (2014)

HIFU immunotherapy: lessons from animal to clinical studies
por: Wu, Feng
Publicado: (2015)

GRAIL: a gene related to anergy in lymphocytes
por: Fathman, G, et al.
Publicado: (2003)

Can we recruit to expertise trials? Experience from the total or partial knee arthroplasty trial (TOPKAT)
por: Davies, Loretta, et al.
Publicado: (2013)

HTLV-1 gene expression by individual infected clones determines susceptibility to lysis by cytotoxic T lymphocytes specific for Tax and HBZ
por: Rowan, Aileen G, et al.
Publicado: (2014)

Can immunotherapy be useful for a « functional cure » of HIV infection?
por: Vanham, Guido
Publicado: (2011)

Bispecific costimulatory molecules for activation of tumor-killing lymphocytes
por: Weth, R, et al.
Publicado: (2004)

Tumor-infiltrating lymphocytes predict cutaneous melanoma survival
por: Fortes, Cristina, et al.
Publicado: (2015)

Crossing of the intestinal barrier by HTLV-1 infected lymphocytes
por: Percher, Florent, et al.
Publicado: (2015)

Endothelial Retargeting of AAV9 In Vivo
por: Bozoglu, Tarik, et al.
Publicado: (2022)

Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
por: Niemann, Julia, et al.
Publicado: (2019)

Focused ultrasound: an effective technique for unleashing the power of immunotherapy in the tumor microenvironment?
por: Repasky, Elizabeth
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_loe4s3v5n4rsj6vpnrkhh3jvjr